NasdaqGM:ATRCMedical Equipment
AtriCure (ATRC): Assessing Valuation Following FDA Clearance of New cryoXT Pain Management Device
If you’re watching AtriCure (ATRC) after their recent announcement, you’re in good company. The launch of the cryoXT device, cleared by the FDA and aimed at easing post-surgical pain for amputation patients, could open new pathways for the company in a segment with significant unmet needs. With over 185,000 amputations annually in the U.S. and high rates of painful complications, even small advances like this can shift how the medical community views a player like AtriCure.
This product news...